Companies Related to "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" [Most Relevant Company Matches] RSS

03:47 EDT 31st October 2014 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive corporate database of over 50,000 company records.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" Companies 1–25 of 1,500+

Extremely Relevant

Cell Medica Limited

Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cancers related to oncogenic viruses. The Company’s lead cell product, CytovirTM CMV, for the treatment and prevention of cytomegalovirus (CMV) infections in patients following al...

Relevant

Profectus BioSciences, Inc.

Profectus BioSciences, Inc. is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases with a goal of reducing morbidity and mortality. Since its inception in 2003, the Company’s strategic intent has been to develop and acquire the technologies needed to deliver on that mission within high value mark...

Barr Pharmaceuticals, Inc

Barr Pharmaceuticals, Inc. is a Delaware holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. The Company’s generic products are marketed under the “Barr” label, and proprietary products are marketed under the “Duramed” label.

Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focused on its proprietary stem cell and T-cell technologies for the autologous use of peripheral blood derived adult stem cells in regenerative medicine as well as T cells for the treatment of autoimmune ...

Inviragen, Inc. and PharmaJet, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

C3

Clinical Cell Culture (C3) is a company listed on the Australian Stock Exchange (ASX Code CCE) that was established to commercialise a number of autologous tissue engineered products for autologous cell replacement.C3 is able to provide culture services from laboratories based in Australia and Europe and is expanding their sales, marketing and clinical support programme throughout the world. This ...

Inviragen, Inc. and Duke-NUS

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease, chikungunya and Japanese encephalitis which affect millions of individuals in Asia. Vaccines in ...

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...

GeneMax

GeneMax develops innovative immunotherapies in the fields of oncology and infectious disease. Our patented technology restores or increases antigen processing and antigen specific immune responses. GeneMax has demonstrated preclinical efficacy in animal models of lung cancer and melanoma as well as proof of principle for infectious disease pathogens.GeneMax’s program also includes developing a t...

BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv Universit...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

Barr Laboratories Incorporated

Barr Laboratories, Inc. is an established pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary prescription pharmaceuticals. The Company was founded in 1970 by Mr. Edwin A. Cohen and a partner, and commenced active business in 1972 as a manufacturer of generic drug products. Barr is listed on the New York Stock Exchange (NYSE-BRL). The Company cur...

Lakewood-Amedex Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Sta...

Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Sta...

Inviragen, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Barr Associates, Inc

Barr Associates is the world's largest independent manufacturer of precision thin film coatings and optical filters. We have an unmatched heritage in the optical filter and coating business with a strong track record spanning over 35 years of providing solutions and parts for some of the most challenging requirements.

Cell Medica

Cell Medica is a clinical stage cellular therapeutics company engaged in the development and delivery of cellular immunotherapy treatment strategies for infectious disease and cancer. The Company’s lead clinical application, referred to as Virus-Specific Immune Reconstitution (VSIR), involves the transfer of donor-derived virus-specific T cells into a...

Variation Biotechnologies Inc

Variation Biotechnologies, Inc. (VBI) creates intelligent vaccines that learn from nature. Our management and scientific team consists of industry-leading experts that have increased our product pipeline and partnerships.After decades of vaccine research, Variosite™ technology evokes the full power of the immune system by mimicking the body's natural protection to infection. This novel vaccine s...

MEDINET Co., Ltd. and MaxCyte, Inc.

MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, quality control, and facility management with respect to the immuno-cell therapy. MEDINET has extensive experience in autologo...

Mymetics Corporation

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase...

Intracel

Intracel is a leading commercial-stage biotechnology company focused on the development of immune therapy to treat cancer. The company’s pipeline includes product development programs in active immunotherapy and fully human monoclonal antibodies. Intracel has completed clinical studies in Colon, Renal and Ovarian carcinoma, as well as Melanoma. Business StrategyRestructured company to focus o...

Bio-Bridge Science

Bio-Bridge Science, Inc., a development stage biotechnology company, engages in the commercial development of vaccines for the prevention and treatment of human infectious diseases. The company is currently developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). It develops HIV vaccines for both preventive and therapeutic purposes. ...

Neotropix, Inc.

The company has signed two key licensing agreements with strong industry partners. These agreements allow Neotropix to use novel therapeutics to conduct research and development on major cancer indications.Neotropix is preparing to begin clinical trials in 2006, and is seeking FDA approval to grant its virus orphan drug status for the treatment of small cell lung cancers. This will be the first ap...

Medizone International

Triatomic Oxygen (O3 or ozone), is the first layer of atmospheric protection interfacing the vastness of the cosmos with Planet Earth. Ozone's healing properties have been known for many years and the use of medical ozone pre-dates WW I. Toxicity was a problem in early medical ozone usage as the drug was produced using compressed air containing nitrogen, rather than medical grade oxygen (O2). The ...

Jason Epstein


More From BioPortfolio on "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine"

Search BioPortfolio:
Loading
Advertisement
Advertisement

Corporate Database Quicklinks